Interview: Kainos Aims To Open New Era With Novel Parkinson’s Drug

Kainos Medicine’s senior vice president sat down with Scrip to talk about the progress and ambitions for its first-in-class, potentially disease modifying Parkinson's disease drug candidate. If the drug candidate successfully goes through a Phase IIa in the US, it is set to draw robust interest from multinational pharmas which are already active in the area that lacks fundamental treatments.